Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics Names New CEO; Ciphergen Sales VP Resigns; Beckman Director Steps Down; and Others

NEW YORK (GenomeWeb News) — Ciphergen Biosystems last week said that James Merryweather will resign as executive vice president of sales and marketing.
Merryweather “principally supported” Ciphergen’s tools business, which the company sold to Bio-Rad late last year.
As part of his resignation, Merryweather will provide consulting services to the company as requested for up to six months following his resignation, agree not to compete with the company or solicit the services of the company's employees, and provide a general release of claims in favor of the company.
In return, Merryweather will continue to be paid at his current base rate for the term of the consulting period.

Beckman Coulter director Hugh Coble will be retiring from the company’s board on Feb. 2, the firm said in a Securities and Exchange Commission filing last week.

Epigenomics this week said it has named Geert Nygaard as its new CEO.
Nygaard comes to the company from his role as managing director and management board member of Abbott. Nygaard also has worked at the Swiss company Dako and at Beckman Instruments.

Strategic Diagnostics this week said it has named Stan Fronczkowski to be chief financial officer and Faye Coggins as executive director of marketing.
Fronczkowski spent 29 years with Keystone Foods, and served as vice president of international finance and COO for Keystone Europe, Middle East and Africa, and as vice president of finance for Asia-Pacific.
Coggins most recently was vice president of marketing for the life science research division of Fisher Biosciences. He has also been executive director for Qiagen.

Cellomics CEO Lansing Taylor has won the 2007 Society for Biomolecular Sciences accomplishment award for commercializing high-content screening, SBS said. The award is presented every year to SBS members who advance the “art and science of drug discovery.”
SBS said that as a result of Taylor’s leadership, HCS has “evolved from a platform focused on instrumentation to an integral part of drug discovery.”

Kim Fechtel is the new senior director of scientific consulting at 3rd Millennium, the company said this.
In the new position, Fechtel will be responsible for business development and will be a principal investigator and scientific leader for R&D grants.

Fechtel is former senior director of bioinformatics at Genome Therapeutics and was involved in bioinformatics projects at Proteome and at the Genetics Institute

Agilent Technologies has promoted Rodney Gonsalvesto the post of director of investor relations, the company said this week.

Gonsalves recently served Agilent as controller of corporate governance and customer financing in the company’s global infrastructure organization. He succeeds Hilliard Terry, who was named vice president and treasurer last November.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.